BECN1 and cholangiocarcinoma: As shown in Figure 3, Beclin 1 high or low expression had the similar 3-year OS rate (high VS low: 21.4% VS 33.0%, P = 0.25) for the overall cholangiocarcinoma patients (Figure 3A), Beclin 1 high expression predicted a favorable 3-year PFS (high VS low: 69.1% VS 46.8%, P = 041, Figure 3B).